A New Type of CPR Announces CPR Therapeutics Inc.

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Today CPR Therapeutics Inc. announced they have completed early-phase proof-of-principal studies of its integrated cardiopulmonary resuscitation (CPR) system.  These studies, undertaken at the Halperin Cardiology Bioengineering Laboratory at the Johns Hopkins Hospital, confirmed the Company’s foundational concept that multiple CPR pump mechanisms can be combined to produce dramatic improvements in hemodynamics.

Norman Paradis MD, the Company’s Founder and CEO stated: “We are pleased that these early studies provided such a strong signal of efficacy.  Hemodynamic improvements of this magnitude are unheard of in resuscitation research.  They strongly indicate that we’re on the right track and that our human prototype system will have a positive clinical trial.”  Dr. Paradis is an emergency medicine physician and Professor at the Geisel School of Medicine at Dartmouth.

Dr. Henry Halperin, the Company’s Chief Scientific Officer: “This is very exciting.  While the hypothesis that multiple CPR pump mechanisms might be synergistically combined had face-validity, it is good to see actual data.”  Dr. Halperin is a cardiologist and the David J. Carver Professor of Medicine at Johns Hopkins University.

In a widely used model of cardiac arrest, the Company’s multimodal CPR resulted in more than 50% improvements in indicators of vital organ perfusion.

Dr. Paradis added “improvements like this are predictive of significantly increased rates of successful resuscitation.  We look forward to continuing with our prototype R&D and moving toward clinical trials.”



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.